Kazia Therapeutics Limited (KZIA)
NASDAQ: KZIA · Real-Time Price · USD
6.15
-0.41 (-6.25%)
Jan 29, 2026, 3:24 PM EST - Market open
Kazia Therapeutics Revenue
In the fiscal year ending June 30, 2025, Kazia Therapeutics had annual revenue of 1.83M AUD, down -26.28%. Kazia Therapeutics had revenue of 1.81M in the half year ending June 30, 2025, with 180,571.00% growth.
Revenue (ttm)
1.83M AUD
Revenue Growth
-26.28%
P/S Ratio
6.00
Revenue / Employee
304,833 AUD
Employees
6
Market Cap
67.01M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 1.83M | -652.00K | -26.28% |
| Jun 30, 2024 | 2.48M | 2.48M | 248,000.00% |
| Jun 30, 2023 | 1,000.00 | -9.00K | -90.00% |
| Jun 30, 2022 | 10.00K | -15.17M | -99.93% |
| Jun 30, 2021 | 15.18M | 14.19M | 1,436.54% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pelthos Therapeutics | 7.41M |
| Equillium | 4.39M |
| ImageneBio | 800.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| Mereo BioPharma Group | 500.00K |
KZIA News
- 2 days ago - Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer - PRNewsWire
- 21 days ago - Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End - PRNewsWire
- 5 weeks ago - Kazia Therapeutics Regains Full Nasdaq Listing Compliance - PRNewsWire
- 7 weeks ago - Kazia Therapeutics Highlights New Clinical and Translational Findings Demonstrating Paxalisib's Ability to Reinvigorate Anti-Tumor Immunity Across Multiple Advanced Breast Cancer Populations including TNBC and HER2+ - PRNewsWire
- 2 months ago - What's Going On With Cancer Firm Kazia Therapeutics - Benzinga
- 2 months ago - Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities - PRNewsWire
- 2 months ago - Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy - PRNewsWire
- 3 months ago - Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner - PRNewsWire